



To whom it may concern

Brno, January 14<sup>th</sup>, 2016

I have met today with Mr. Rinder Ionut, father of Cristian Andrei Rinder, DOB 04082012, who is suffering from – what I understand from his medical reports – as chemoresistant Burkitt's lymphoma. The boy is so far under the care of Pediatric Oncology Department in Timisoara, recently the R-ICE block was given, after progression following DHAP and different BFM based cycles.

In this situation, there is not available any appropriate clinical study open which would be available for international patients. In such situation the only potentially curative chance is theranostic approach, which means, individualized, personalized approach to each individual patient, reflecting his own tumor biology.

Our proposal here would be

- 1) to confirm the diagnosis from original blocks
- 2) to make new biopsy in order to perform
  - a. whole transcriptome + phosphoproteomic analysis
  - b. to propose individual treatment based on tumor biopsy results.
- 3) Moreover, autologous dendritic cell vaccine could be prepared for the patient as add on strategy together with other drugs.

Estimated costs of such complex personalized treatment is about 80 000 Euro for 4 months treatment.

Dendritic cell vaccine is

17 000 Euro

Costs of special drugs /biologics/ will depend on tumor analysis results, however, real estimate 30 000 Euro

Laboratory analysis costs

8 000 Euro

Hospital costs /hospital stay, infusions, antibiotics, ICU etc../ 25 000 Euro

University Hospital Brno  
Pediatric Oncology Department  
Cernopolní str. 9, 625 00 Brno  
Czech Republic

.....  
Jaroslav Štěrba, MD., Ph.D.  
Professor of Oncology and Pediatrics

The Head, Ped. Oncology Dpt. University Hospital Brno